The value of routine blood test parameters obtained at admission to predict acute stent thrombosis in patients with st-segment elevation myocardial infarction

The purpose of this study was to investigate whether biochemical parameters on admission can predict the development of acute stent thrombosis within 24 hours of presentation in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI). This retrospective study included patients who were hospitalized for acute STEMI and treated with primary PCI between September 2009 and May 2018. The patients were divided in to two groups according to the presence or absence of acute stent thrombosis following primary PCI. After comparison of biochemical parameters in the two groups, variables displaying difference between the two groups were further analyzed for their predictive role in stent thrombosis. Two hundred and twenty-two STEMI patients treated with primary PCI were enrolled in the study. Among these, 102 experienced acute stent thrombosis within 24 hours of presentation. There was no significant difference instant diameter, stent length and ejection fraction between the groups. Age ,gender, diabetes, hypertension and smoking status were comparable between the two groups. Serum bilirubin and uric acid levels were significantly higher in the stent thrombosis group than the non-stent thrombosis group. Logistic regression analysis revealed that uric acid (OR: 1.482, 95% CI: 1.23-2.342, p=0.034) and total bilirubin (OR: 1.733 95% CI: 1,12-2.046, p= 0.003) levels were significant predictors for stent thrombosis in subjects admitted with STEMI. Admission serum bilirubin and uric acid levels may predict acute stent thrombosis in STEMI patients undergoing primary PCI.

PDF

___

1. Gopalakrishnan M, Lotfi AS. Stent thrombosis. Semin Thromb Hemost. 2018;44:46-51.

2. Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344- 51.

3. Claessen BE, Henriques JP, Jaffer FA, et al . Stent thrombosis: a clinical perspective. JACC: Cardiovasc Interv. 2014;7:1081-92.

4. Pafili K, Penlioglou T, Mikhailidis DP, et al. Mean platelet volume and coronary artery disease. Curr Opin Cardiol. 2019;34:390-8.

5. den Harder AM, de Jong PA, de Groot MCH et al. Commonly available hematological biomarkers are associated with the extent of coronary calcifications. Atherosclerosis. 2018;275:166-73.

6. Machado GP, Araujo GN, Carpes CK et al. Temporal pattern of neutrophilto-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2019;30:631-3.

7. Baktir AO, Sarli B, Demirci E et al. gamma-Glutamyl transferase activity and the burden of coronary atherosclerosis in patients with ST-segment elevation myocardial infarction. Angiology. 2014;65:812-6.

8. Tian TT, Li H, Chen SJ et al. Serum uric acid as an independent risk factor for the presence and severity of early-onset coronary artery disease: a casecontrol study. Dis Markers .2018;2018:1236837.

9. Jain V, Ghosh RK, Bandyopadhyay D et al. Serum bilirubin and coronary artery disease: intricate relationship, pathophysiology, and recent evidence. Curr Probl Cardiol. 2019;22:100431.

10. Ghem C, Sarmento-Leite RE, de Quadros AS, et al. Serum bilirubin concentration in patients with an established Coron Artery Dis. Int Heart J. 2010;51:86-91.

11. Yu J, Han J-L, Wang G-S, et al. Serum total bilirubin levels and disease severity in patients with stable coronary artery disease. Herz. 2017;42:403- 10.

12. Celik T, Kaya MG, Akpek M et al. Does Serum Bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI. Angiology. 2014;65:198-204.

13. Hamur H, Duman H, Bakirci EM et al. Bilirubin levels and thrombus burden in patients with ST-segment elevation myocardial infarction. Angiology. 2016;67:565-70.

14. Vuruşkan E , Düzen IV ,Saraçoğlu E. Periferik arter girişimlerinde artmış tromboembolik risk: ortalama trombosit hacmi ve bilirubin düzeyi. MN Kardiyoloji. 2016;23:164-170.

15. Okuhara K, Kisaka T, Ozono R et al. Change in bilirubin level following acute myocardial infarction is an index for heme oxygenase activation. South Med J. 2010;103:876-81.

16. Gul M, Uyarel H, Ergelen M et al. Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2013;111:166-71.

17. Wu AH, Gladden JD, Ahmed M, et al. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4-7.

18. Egas-Izquierdo M, Wong-Achi X, Alvarado-Villa G,et al. Relation between serum uric acid levels with the degree of coronary artery disease: A prospective study from Ecuador. Clin Investig Arterioscler. 2019;31:8-14.

19. Ozturk D, Celık O, Akın F et al. Usefulness of the uric acid and CHA2DS2- VASc score in prediction of left atrial thrombosis in patients with mitral stenosis and sinus rhythm. Cardio l J. 2015;22:336-42.

20. Atıl A, Deniz A. Could be serum uric acid a risk factor for thrombosis and/ or uveitis in Behcet’s disease? Vascular. 2018;26:378-86.